Hematology

Latest News

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
April 10th 2025

Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

Jared Kaltwasser
Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.
Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
April 8th 2025

Immune Microenvironment a Key Target in CLL

Jared Kaltwasser
A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).
Health equity concept | image credit: VectorMine - stock.adobe.com
April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD
Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).
CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com
April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

Maggie L. Shaw
In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.
Targeting GPRC5D Holds Promise in Multiple Myeloma
April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.
Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg
April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser
The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.
Andrew Kuykendall, MD, Moffitt Cancer Center
April 1st 2025

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

Maggie L. Shaw Andrew Kuykendall, MD
In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable patients to live a more viable life and free them from being tethered to the need for regular phlebotomies.
FDA approval-Olivier Le Moal-stock.adobe.com
March 28th 2025

FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B

Giuliana Grossi
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on the safety and efficacy of fitusiran (Qfitlia; Sanofi).
ESA treatment before or early after regular transfusion therapy improved OS In lower-risk MDS, a new study found. | Image credit: MdBabul - stock.adobe.com
March 28th 2025

ESA Treatment Improves OS in Lower-Risk MDS

Rose McNulty
Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival (OS) In lower-risk myelodysplastic syndromes (MDS), a new study found.
Ajai Chari, MD
March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Kyle Munz Ajai Chari, MD
For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.
ASH logo | images: ASH
March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

Mary Caffrey
The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.
CAR T | Image Credit: © Funny-stock.adobe.com
March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Maggie L. Shaw
Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Woman taking pills from bottle | Image credit: Rawpixel.com – stock.adobe.com
March 20th 2025

In CLL, Zanubrutinib Shows Better Safety Profile Than Ibrutinib

Hayden E. Klein
A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events among those treated with zanubrutinib compared with ibrutinib.
Orca-T is manufactured with highly purified regulatory T cells, hematopoietic stem cells, and conventional T cells from peripheral blood from matched donors. | Image credit: fotogurmespb - stock.adobe.com.jpg
March 20th 2025

Orca-T Immunotherapy Improves cGVHD-Free Survival in ALL, AML, MDS

Rose McNulty
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who received standard allogeneic stem cell transplant for hematologic malignancies.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 19th 2025

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

Maggie L. Shaw Andrew Kuykendall, MD
Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for men vs women.
CLL | Image credit: jarun011 – stock.adobe.com
March 19th 2025

Newer CLL Therapies Show Superior Long-Term Disease Control

Hayden E. Klein
Researchers also highlighted the significance of TTNT-D as a real-world measure of treatment efficacy, noting it provides insight into both clinical and patient-centered outcomes.
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
March 17th 2025

Gene Editing for Safer CAR T-Cell Therapy in Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma.
Modulating cholesterol metabolism in patients with CLL could improve T-cell function and possibly open up new therapeutic avenues to treat the disease. | Image credit: keetazalay - stock.adobe.com
March 11th 2025

Modulating Cholesterol Metabolism Could Open Therapeutic Pathways in CLL

Jared Kaltwasser
Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.
Fred Locke, MD, Moffitt Cancer Center and Research Institute
March 7th 2025

Overcoming Delays in CAR T for Large B-Cell Lymphoma

Maggie L. Shaw Frederick L. Locke, MD
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy donor cells.
Andrew Kuykendall, MD, Moffitt Cancer Center
March 5th 2025

Managing Polycythemia Vera to Reduce Risks and Improve Lives

Maggie L. Shaw Andrew Kuykendall, MD
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells.
Ibrutinib tablets | Image credit: CLShebley – stock.adobe.com
March 5th 2025

Ibrutinib Benefits R/R CLL, but Combo Therapy Works Better

Hayden E. Klein
Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it with other therapies can improve response rates and may allow for treatment discontinuation in some patients.
BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com
February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Sabarish Ayyappan, MD
February 27th 2025

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Kyle Munz Sabarish Ayyappan, MD
More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.
Sabarish Ayyappan, MD
February 24th 2025

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Kyle Munz Sabarish Ayyappan, MD
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
Frederick L. Locke, MD
February 24th 2025

Allogeneic vs Autologous CAR T-Cell Therapy Explained

Maggie L. Shaw Frederick L. Locke, MD
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy produced durable responses in relapsed/refractory large B-cell lymphoma.
Sabarish Ayyappan, MD
February 20th 2025

Geographic Barriers Impede Access to Novel Cancer Treatments

Kyle Munz Sabarish Ayyappan, MD
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com
February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

Kyle Munz
A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.
Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.
FDA approval | Image Credit: © wladimir1804 - stock.adobe.com
Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Maggie L. Shaw
Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).
Patient talking to doctor in appointment. | Image credit: Chinnapong – stock.adobe.com
February 10th 2025

Academic Cancer Centers See Longer Survival in CLL, MCL Than Community Centers

Hayden E. Klein
Patients treated in community settings were more likely to be older, less likely to be White, and had worse survival rates, highlighting disparities in specialized cancer care.
<12345678
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo